Year: 2017

DGAP-News: Epigenomics AG / Key word(s): Contract 03.03.2017 / 11:40 The issuer is solely responsible for the content of this announcement. Press ReleaseEpigenomics AG: U.S. Department of Veterans Affairs awards supply contract for Epi proColon(R)Berlin (Germany) and Germantown, MD (U.S.A.), March 3, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), today announced that […]

DGAP-News: Epigenomics AG / Key word(s): Miscellaneous27.02.2017 / 13:30The issuer is solely responsible for the content of this announcement.—————————————————————————Epigenomics Joins Forces with hundreds of Organizations to IncreaseColorectal Cancer Screening Rates in the United States”80% by 2018″ is a shared goal to have 80% of adults aged 50 and olderscreened for colorectal cancer by 2018 – […]

DGAP-News: Epigenomics AG / Key word(s): Study 14.02.2017 / 09:45 The issuer is solely responsible for the content of this announcement. Press release Journal of Molecular Diagnosis & Therapy publishes review of blood-based screening test Epi proColon(R) 2.0 CE Liquid biopsy test delivers high sensitivity and specificity and may increase participation in cancer screening programs […]

DGAP-Media / 30.01.2017 / 10:00 Press release Epigenomics AG: Systematic study review supports use of Epi proColon(R) in blood-based cancer detection Meta-analysis published in renowned journal “Clinical and Translational Gastroenterology” Berlin (Germany) and Germantown, MD (U.S.A.), January 30, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that the scientific results of a […]

DGAP-News: Epigenomics AG / Key word(s): Scientific publication 11.01.2017 / 08:33 The issuer is solely responsible for the content of this announcement. Press release Journal of “Cancer Treatment and Research Communications” Publishes Results of Study with Blood Test Epi proColon(R) ADMIT Study Results Demonstrate Higher Uptake of a Colorectal Cancer Screening Blood Test Compared to […]